The present study will evaluate the use of osimertinib as 1st line therapy for patients with advanced EGFR positive non-small cell lung cancer who are treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.

This will be an observational, multicentric, retrospective/ prospective analysis of patients with advanced EGFR positive non-small cell lung cancer that receive osimertinib as 1st line therapy. The patient data will be collected at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology during scheduled patient clinical visits, from February 2020 for a total period of three years. The biological material obtained from the patients of this analysis will be possibly used in a future translational study as an exploratory analysis.

Inclusion Criteria:

• men or women of 18 years or older that live in Greece
• histologically or cytologically confirmed, advanced EGFR positive non-small cell lung cancer
• untreated patients for advanced NSCLC
• patients who are expected to receive osimertinib regardless of their enrollment in the study
• signed written informed consent

Exclusion Criteria:

• patients with cancer other than NSCLC that require treatment
• pretreated patients for NSCLC
• patients that receive or are expected to receive or have received an investigational drug/product/intervention

patients with advanced EGFR positive non-small cell lung cancer that receive osimertinib as 1st line therapy and are treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology